j9ÓÎÏ·

j9ÓÎÏ·-j9ÓÎÏ·¹ÙÍø

¡¾ÂÛÎÄ·ÖÏí¡¿¿¹ÉúËØÓÕµ¼¸ïÀ¼ÒõÐԸ˾ú¿ªÊÍÄÚ¶¾Ëصij¢ÊÔ×êÑÐ(Ò»)

°ä²¼¹¦·ò£º2019-10-17
·ÖÏíµ½£º

¹Ø¼ü´Ê£º

¿¹ÉúËØ¡¢Ï¸¾úÄÚ¶¾ËØ¡¢Ï°È¾¡¢j9ÓÎÏ·¡¢ÀÖɽö×Éú¿Æ²úÆ·½éÉÜ¡£


ÌáÒª£º

³¢ÊÔÂÛÎÄÔ̺¬³¢ÊÔÖ÷ÕÅ¡¢³¢ÊÔ²½Öè¡¢³¢ÊÔÁ˾ֺͳ¢ÊÔ½áÂÛËIJ¿ÃÅ¡£


ÐìÄÜÎä¡¡Ô¬½¨³É¡¡Ð¤¹âÏÄ¡¡Ö£½­¡¡ÇØÐ¢½¨

Æù½ñΪֹ,ϰȾÓÈÆäÊǸïÀ¼ÒõÐÔ(G-)¸Ë¾úϰȾµ¼ÖµÄŧ¶¾Ö¢¼°Å§¶¾ÐÔÐÝ¿Ë,ÈÔÊÇÑϳÁÉÕÉË¡¢´´ÉË»¼ÕßµÄÖØÒªéæÃüÔ­ÒòÖ®Ò»[1,2],¶ø¿¹ÉúËØµÄʹÓÃÊÇÒ½ÖÎG-¾úϰȾµÄ³ÁÒª¼¿Á©¡£µ«½üÄêÀ´µÄ×êÑÐÅú×¢[3- 6]:ÀûÓÃijЩÃô¸Ð¿¹ÉúËØÒ½ÖÎG-¾úϰȾʱ,ËäÄÜÓÐЧɱÃðϸ¾ú,ȴͬʱÓÕµ¼G-¾ú¿ªÊÍ´óÁ¿ÄÚ¶¾ËØ(lipopolysaccharide, LPS),ÆäÓÕµ¼Á¦Òò¿¹ÉúËØµÄÖÖÀà·ÖÆç¶øÒì¡£LPSÊÇÉÕÉËŧ¶¾Ö¢¼°Å§¶¾ÐÔÐݿ˷¢²¡»úÔìÖеĹؼüÖ²¡Òò×Ó,µ«Ä¿Ç°ÉÐÎ޿ɹ©ÁÙ´²ÊµÓõÄLPSÞ׿¹¼Á[7,8],Òò¶ø·ÖÆç¿¹ÉúËØÓÕµ¼G-¾ú¿ªÊÍLPSÄÜÁ¦µÄ²î¾à,×îÖÕ½«Ó°Ïìµ½Ò½ÖγÉЧ¡£±¾³¢ÊÔÑ¡ÔñĿǰÁÙ´²ÉÏG-¾úϰȾÖÐ2ÖÖÖØÒªµÄÖ²¡¾úÂÌŧ¸Ë¾úºÍ´ó³¦¸Ë¾ú,ͬʱѡÔñ×î³£ÓõÄ3À࿹ÉúËØ:¦Â-ÄÚõ£°·Àà¡¢à­ÅµÍªÀ༰°±»ùÌÇß°Àà,¹Û²ìÆä¶ÔÌå±íÂÌŧ¸Ë¾úºÍ´ó³¦¸Ë¾úµÄɱ¾úЧÁ¦¡¢Ï¸¾ú״̬ѧ±ä¶¯¡¢ÓÕµ¼Ï¸¾ú¿ªÊÍLPSÄÜÁ¦µÈ,ΪÁÙ´²Ò½ÖÎG-¾úϰȾʱ,ÕýÈ·Ñ¡Ôñ¿¹ÉúËØÌṩ³¢ÊÔÆ¾¾Ý¡£


×ÊÁÏÓë²½Öè

Ò»¡¢×ÊÁÏ

1.ϸ¾ú:ÂÌŧ¸Ë¾ú(Pseudomonas aeruginosa103,PA103)ºÍ´ó³¦¸Ë¾ú(Escherichia coli 25922,E.coli 25922),ÓɵÚÈ«¾üÒ½´óѧ΢ÉúÎï½ÌÑÐÊÒÌṩ¡£


2.¿¹ÉúËØ:Ñǰ·ÅàÄÏ(Imipenem, IMP),ÃÀ¹úĬ¿Ë¹«Ë¾Ä¬É³¶«Ò©³§,ÅúºÅV5134¡£Í·æßËûà¤(Cef-tazidime, CTZ),Ó¢¹ú¸ðÀ¼ËØÍþ¿µ¹«Ë¾,ÅúºÅB4166GA¡£ÅรÐÂ(Pefloxacine, PFX),·¨¹úÂÞÄÂí½Åʿ˹«Ë¾ÀÖ°²ÔìÒ©³§,ÅúºÅ114¡£ÁòËá¶¡°·¿¨ÄÇÃ¹ËØ×¢ÉäÒº(Amikacin sulfate Injection, AMN),ÉϺ£Ðñ¶«º£ÆÕÒ©ÒµÓÐÏÞ¹«Ë¾,ÅúºÅ970307¡£


3.ÊÔ¼Á:(1)ö×ÊÔÑéרÓÃj9ÓÎÏ·,ÀÖɽj9ÓÎÏ·ÉúÎï¿Æ¼¼,ÅúºÅ980225;j9ÓÎÏ·ÈÜ»¯Ë®,ÀÖɽj9ÓÎÏ·ÉúÎï¿Æ¼¼,ÅúºÅ980125¡£


C73A8951_°®ÆæÒÕ.jpg


×¢£º³¢ÊÔ²½Öè´Ë´¦Ê¡ÂÔ £¬ÈçÓбØÒª¿ÉÁªÏµÎÒ˾»ñÈ¡¡£



£¨Ê¡ÂÔ²¿Ãų¢ÊÔÁ˾֣©

³¢ÊÔÁ˾Ö


1.¿¹ÉúËØ·õÓýºóϸ¾ú¾úÁ¿±ä¶¯:(1)³ý0.5 MIC±í,4ÖÖ¿¹ÉúËØ±ðÀëÒÔÖÕŨ¶È1¡¢5¡¢10MIC×÷ÓÃÓÚÂÌŧ¸Ë¾ú,¸÷ʱÏàµãϸ¾ú¾úÁ¿Óë¶ÔÕÕ×éÏà±ÈÏÔÖøÏ÷¼õ,ÆäÖÐÒÔIMPɱ¾ú×÷ÓÃ×î¿ì,CTZºÍPFX´ÎÖ®,AMN½Ï²î,µ«4ÖÖ¿¹ÉúËØÖ®¼ä²î¾àÎÞͳ¼ÆÑ§Òâ˼,¼ûͼ1¡£(2)4ÖÖ¿¹ÉúËØ±ðÀëÒÔ0.5¡¢1¡¢5¡¢10 MICÖÕŨ¶È×÷ÓÃÓڴ󳦸˾ú,ɱ¾úÇúÏߵı䶯Ç÷Ïò¼°¿¹ÉúËØÉ±¾úЧÁ¦¼äµÄ²î¾àÓëPA103×éÀàËÆ¡£


΢ÐÅͼƬ_20191017091045.png

΢ÐÅͼƬ_20191017091049.png

2.¿¹ÉúËØÓÕµ¼Ï¸¾ú¿ªÊÍLPSµÄ±ä¶¯:(1)¶ÔÕÕ×é:Ëæ×Å·õÓý¹¦·òµÄµ¢¸é,Á½ÖÖϸ¾ú×Ô¾õ¿ªÊÍLPSµÄÁ¿Öð²½Ôö³¤,¸÷¸öʱÏàµã´ó³¦¸Ë¾úµÄLPSˮƽÏÔÖø¸ßÓÚÂÌŧ¸Ë¾ú,Á½Õß¼äµÄ²î¾àÓÐÏÔÖø»ò¼«¶ÈÏÔÖøÐÔÒâ˼(P< 0.05¡« 0.01,±í1)¡£(2)¿¹ÉúËØ×é:µ±4ÖÖ¿¹ÉúËØÒÔ0.5¡¢1¡¢5ºÍ10 MICŨ¶È±ðÀë×÷ÓÃÓÚÁ½ÖÖϸ¾úºó,¾ù¿ÉÓ°Ïìϸ¾úLPSµÄ¿ªÊÍ,ÆäÓÕµ¼Á¦Ó뿹ÉúËØµÄÖÖÀࡢŨ¶È¡¢×÷Óù¦·ò¼°¾úÖÖÓйØ¡£


3.¿¹ÉúËØÖÖÀàºÍ×÷Óù¦·òµÄÓ°Ïì:µ±4ÖÖ¿¹ÉúËØÅ¨¶ÈºÍ×÷Óù¦·òÒ»Ñùʱ,ϸ¾ú¿ªÊÍLPSµÄÓÕµ¼Á¦Îª:CTZ> PFX> IMP> AMN¡£Ëæ×Å¿¹ÉúËØ×÷Óù¦·òµÄµ¢¸é,ÓÕµ¼Ï¸¾ú¿ªÊÍLPSµÄÁ¿Ò²Öð²½Ôö³¤,µ«¸÷ʱÏàµã¿ªÊ͵ÄËٶȲ¢²»Ò»Ñù(ͼ2)¡£


΢ÐÅͼƬ_20191017091053.png

΢ÐÅͼƬ_20191017091057.png



²¿ÃŲο¼Îļþ

1¡¡Glauser M P, Heumann D, Baumgartner J D, et al. Pathogenesisand potential strategies for prevention and treatment of septicshock: an update. Clin Infect Dis,1994,18:S205- 216.

2¡¡Holzheimer RG,Hirte J F, Reith B,et al.Different endotoxin re-lease and IL- 6 plasma levels after antibiotic administration in sur-gical intensive care patients. J Endotoxin Res,1996,3:261- 267.

3¡¡Jackson J J, Kropp H.Differences in mode of action of¦Â- lactamantibiotics influence morphology, LPS release and in vivo antibioticefficacy. J Endotoxin Res,1996,3:201- 218.

4¡¡Healy DP, Verst- Brasch CL, Clendening CE, et al. Influence ofdrug class and dose size on antibiotic- induced endotoxin/ IL- 6release and impact on efficacy of anti- endotoxin antibody.J Endo-toxin Res,1996,3:219- 227.

5¡¡Prins JM.Antibiotic induced release of endotoxin- clinical date andhuman studies. J Endotoxin Res,1996,3:269- 273.

£¨ÎÄÕºͲ¿ÃÅͼƬÆðÔ´ÓÚÍøÂç £¬ÈçÓÐÇÖȨÁªÏµÉ¾³ý£¡£©



¡¾ÍøÕ¾µØÍ¼¡¿